Business
IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
RESEARCH TRIANGLE PARK, N.C., May 13, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. Kexing Biopharm (Stock Code: 688136.SH) is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales
About this update from Iqvia Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":546,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/73111d87c16df5838f936ec6fa77fe1c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ytypp9lJYQu8d_Vs5AM4ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/73111d87c16df5838f936ec6fa77fe1c","width":546,"height":209},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/mXXmzwoSiuHSj3JD56CmNQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/73111d87c16df5838f936ec6fa77fe1c","width":546,"height":209}},"lazy":false},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 13, 2026--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. Kexing Biopharm (Stock Code: 688136.SH) is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological preparations.","length":583,"tagName":"p"},{"type":"text","content":"The collaboration is designed to support Kexing’s global expansion by bringing together IQVIA’s end-to-end capabilities across the development lifecycle. By aligning clinical development, regulatory strategy, advanced analytics and commercialization under a coordinated global approach, the program aims to accelerate biosimilar development for international markets while upholding rigorous standards for quality and scientific integrity.","length":439,"tagName":"p"},{"type":"text","content":"In parallel, the collaboration integrates IQVIA’s AI‑enabled clinical trial capabilities to enhance speed, efficiency and confidence in decision-making throughout development. The use of AI across key activities — from protocol design to site identification and study conduct — will help streamline execution and improve overall trial performance.","length":347,"tagName":"p"},{"type":"text","content":""Through this collaboration, we are supporting Kexing as it progresses its global biosimi...